By 2017, Alydia, the FDA, and the clinical trial sites ... or while contractions or medical interventions were underway. Courtesy of Organon That matter settled, Morrissey’s team moved onto ...

Vivek Soares appointed as Organon India's new country lead, succeeding Anjan Sen who retires after 35 years in the biopharmaceutical sector, including 11 years with MSD and Organon. Prior to ...

Also in 2022, Organon licensed the global rights to Xaciato ... through its acquisition of Alydia Health. The Jada System is designed to encourage normal contraction of the uterus to stop ...

Several authors disclosed ties to Organon/Alydia Health, which funded the study, and to pharmaceutical and medical technology companies.

Several authors disclosed ties to Organon/Alydia Health, which funded the study, and to pharmaceutical and medical technology companies. More information: Dena Goffman et al, Real-World ...

The company’s strategic adviser, Anne Morrissey, was formerly CEO of Alydia Health, whose unique product to control postpartum hemorrhage was sold to Organon in 2021 for $240 million. Its principal ...

It was first approved by the US Food and Drug Administration (FDA) in 2020. Organon obtained the rights to the JADA system when it acquired Alydia Health in 2021. “Appropriate management of abnormal ...

Organon is one of the few companies with the ... which we added to our portfolio in 2021 with the acquisition of Alydia Health. JADA is a device indicated to provide control and treatment of ...

Alydia Health was acquired by Organon in 2021. Study sites received research-related financial support, but none of the authors received direct payments from Alydia Health/Organon. Goffman serves ...

In June, Organon completed its acquisition of Alydia Health, a medical device company focused on postpartum hemorrhage and abnormal postpartum uterine bleeding.